IDEAYA Q2 2026: $1.24B Cash Runway, Darovasertib NDA on Track, Pipeline Momentum Builds
IDYA sits 63% above its 52-week low of $22.09.
Summary
IDEAYA's Q2 2026 filing reveals $1.24B in cash, positive darovasertib data, and an NDA submission on track for H2 2026. R&D spending has risen sharply as the pipeline advances, yet the balance sheet stays robust following a $345M follow-on offering.
Key Events · Earnings and Guidance · IDYA
-
Darovasertib NDA on Track
Positive Phase 2/3 OptimUM-02 data supports an NDA submission in H2 2026 for metastatic uveal melanoma, with the FDA's Real-Time Oncology Review program being utilized.
-
Strong Cash Position
Cash, equivalents, and marketable securities totaled $1.24 billion as of June 30, 2026, bolstered by a $345 million follow-on offering that closed in June.
-
R&D Spending Surge
Research and development expenses rose 41% year-over-year to $204.4 million for H1 2026, driven by the advancement of darovasertib, IDE849, IDE034, and other programs.
-
New Collaborations
During the quarter, clinical supply agreements were entered with AstraZeneca for IDE849 plus Imfinzi, and with Roche for IDE892 plus a pan-RAS inhibitor.
Analysis · IDYA · Life Sciences
A robust $1.24 billion in cash and equivalents gives IDEAYA a runway well beyond 12 months, according to its Q2 2026 10-Q. The quarter's highlight was positive Phase 2/3 data for lead asset darovasertib, keeping an NDA submission on schedule for the second half of 2026. Reflecting broad pipeline progress—including new clinical collaborations with AstraZeneca and Roche—R&D spending jumped 41% year-over-year to $204.4 million for the first half. A $345 million follow-on offering closed in June further fortified the balance sheet. While the net loss widened to $112.5 million for the quarter on increased clinical activity, the cash position and upcoming catalysts leave the investment thesis intact.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDYA was trading at $36.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $22.09 to $40.58. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.